IntegraGen Hires New VP; Xenomics Names CEO; Seattle Genetics Loses CFO; Techno Venture Fleshes Out Staff

IntegraGen has appointed David Brady as vice president. He comes to the company from Biogen Idec, where he was associate director for international corporate development.

Before working at Biogen, Brady was commercial manager for Lonza Biologics, part of the Alusuisse Lonza group providing contract management services to the biopharmaceutical industry. He has a BSc in biochemistry from the Universityof Liverpooland an MBA from Warwick Business School.

Xenomics has hired V. Randy White as CEO. White, a former CEO of Nanogen,  has been an executive with National Health Laboratories Holdings and American Medical Laboratories.

Douglas Williams has resigned his post as chief scientific officer and executive vice president of research and development at Seattle Genetics. According to the Bothell, Wash.-based firm, Williams has stepped down to accept a position with another undisclosed company.

Adrian Butash was named executive vice president and chief marketing officer of Applied DNA Sciences. Butash formerly served as a marketing executive with Celanese and Hoechst Fibers. He also ran his own marketing/advertising agency in New Yorkcalled Adrian. Los Angeles-based Applied DNA Sciences makes a bio-digital microchip that is used for security and anti-counterfeit applications.

Additionally, TVM expanded its life science research team in Bostonby appointing Jens Eckstein as a principal and Bong Koh as associates. 

Fischer joined TVM in September 2000 after three years as a consultant in the corporate finance department of KPMG Deutsche Treuhand-Gesellschaft. He will concentrate on all issues of corporate finance involving the TVM portfolio companies.

De Baey joined TVM in April 2001. She is responsible for identifying and assessing investment opportunities and the analysis of the scientific background of business ideas. She came to TVM from Micromet in Martinsried, Munich, where she led a research group on the development of therapeutic vaccines.

Before joining TVM in 2004, Eckstein was director of lead discovery and research IT at Enanta Pharmaceuticals, as well as head of research groups in biochemistry, structural biology, and computational chemistry at Mitotix, which is now called GPC-Biotech.

Koh, who joined TVM in April, was previously a biopharmaceutical R&D strategy analyst at The Boston Consulting Group.

Promoted? Changing jobs? GenomeWeb Newswants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.